Living Cell Technologies Ltd. Receives Approval to Progress Its Human Phase II Trial of DIABECELL(R) Treatment for Diabetes to Next Stage with Encouraging Data

SYDNEY & AUCKLAND, New Zealand--(BUSINESS WIRE)--Living Cell Technologies Limited (ASX:LCT) (OTCQX:LVCLY), a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.